IXICO plc provides technology enabled services to the biopharmaceutical industry worldwide. The company's technologies include Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, QC, and reading/analysis to reporting and data transfer. The company offers end-to-end imaging services, primarily in the fields of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, cerebrovascular, and progressive supranuclear palsy diseases; and engages in the data collection and analysis of neurological diseases. Its services are used to select patients for clinical trials, assess the safety and efficacy of new drugs in development, and in post marketing surveillance. The company was incorporated in 1995 and is based in London, the United Kingdom.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+44-20-37637499
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees67
OptionableNot Optionable
Ixico (LON:IXI) Frequently Asked Questions
What is Ixico's stock symbol?
Ixico trades on the London Stock Exchange (LON) under the ticker symbol "IXI."
How were Ixico's earnings last quarter?
Ixico Plc (LON:IXI) released its earnings results on Tuesday, December, 4th. The company reported ($2.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.50) by $0.50. View Ixico's Earnings History.
Has Ixico been receiving favorable news coverage?
Headlines about IXI stock have been trending neutral recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ixico earned a coverage optimism score of 0.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the next several days.
Who are some of Ixico's key competitors?
Some companies that are related to Ixico include 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), AorTech International (AOR), Arix Bioscience (ARIX), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Axovant Sciences (AXGT), Biocure Technology (CURE), Biotest (BIO) and Bioventix (BVXP).
Who are Ixico's key executives?
Ixico's management team includes the folowing people:
- Mr. Giulio Cerroni, CEO & Director (Age 56)
- Prof. Derek Lionel Glendon Hill, Co-Founder and Pres of Regulatory Science & External Relations (Age 52)
- Mrs. Susan Day Lowther FCMA, CFO, Company Sec. & Exec. Director (Age 58)
- Prof. Daniel Rueckert, Co-Founder & Member of Scientific Advisory Board
- Prof. David Hawkes, Co-Founder & Member of Scientific Advisory Board
How do I buy shares of Ixico?
Shares of IXI and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Ixico's stock price today?
One share of IXI stock can currently be purchased for approximately GBX 31.
What is Ixico's official website?
How can I contact Ixico?
Ixico's mailing address is 4th Fl, Griffin Court, 15 Long Lane, LONDON, EC1A 9PN, United Kingdom. The company can be reached via phone at +44-20-37637499.
MarketBeat Community Rating for Ixico (LON IXI)
MarketBeat's community ratings are surveys of what our community members think about Ixico and other stocks. Vote "Outperform" if you believe IXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
